Skip to content Skip to footer
SER-252 Advances as the Bullish Case Moves From Platform Promise to Clinical Execution For a small biotechnology company, progress is best measured in patients dosed, safety reviews completed and the quality of the next clinical question. By those measures, Serina Therapeutics (NYSE American:…
Serina's SER-252 Puts a Practical Innovation at the Center of the Story Biotechnology often commands attention by promising an entirely new molecule. Serina Therapeutics (NYSE American: SER) is pursuing a different proposition: take an established therapeutic agent, improve how it reaches the patient and…
A substantial takeover premium highlights the value of differentiated medicines, while Serina Therapeutics and Eupraxia Pharmaceuticals approach clinical milestones of their own. October 19, 2026 Biotechnology investors received a rather emphatic reminder Monday that pharmaceutical innovation can still command a premium, even…
Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…
AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…